Sorafenib

Catalog No.S7397 Synonyms: BAY 43-9006

Sorafenib Chemical Structure

Molecular Weight(MW): 464.82

Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 670 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 62 Publications

9 Customer Reviews

  • Inhibition of the MAPK signaling pathway results in downregulation of Plk-1 protein expression. (a) WB analysis for Plk-1 protein after treatment of human melanoma cell lines M14 and WM-115 with MEK 1/2 inhibitor PD98059 (10 μM), JNK inhibitor (16 μM), p38 inhibitor SB203580 (20 μM), and multikinase inhibitor sorafenib (10 μM) for 48 h showing significant reduction in the expression of Plk-1 protein after 48 hours. (b) Annexin V/PI staining of cells treated with MAPK inhibitors and induction of apoptosis. JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MEK 1/2, mitogen-activated protein kinase kinase 1/2; Plk-1, polo-like kinase 1; WB, western blot.

    J Invest Dermatol 2011 131, 1886–1895. Sorafenib purchased from Selleck.

    (A) were exposed to 200 uM gentamicin for various time periods. Immunoreactivity for phosphorylated JNK (green) and c-Jun (blue) in hair cells increased in a time-dependent manner. B. Hair cells from explants pre-treated with 500 nM sorafenib displayed a near complete inhibition of JNK activation at all time points analyzed.

    J Neurosci 2013 33(7), 3079-93. Sorafenib purchased from Selleck.

  • Sorafenib in combination with metformin or the AMPK activator salicylate enhances AMPK activation. a, b, AMPK activation with the combination of sorafenib and metformin in LKB1 mutant KRAS mutant (A549 and H460) NSCLC cells (a), LKB1 wild-type KRAS mutant (H358) (b, left panel) or LKB1 mutant KRAS wild-type (H838) NSCLC cells (b, right panel). Cells were treated for 48 hr with sorafenib (1-3 uM), metformin (1–1.5 mM) or the combination of sorafenib and metformin with the same concentrations as were used for the individual treatments. c, AMPK activation with the combination of sorafenib and salicylate in LKB1 mutant KRAS mutant (A549 and H460) or LKB1 mutant KRAS wild-type (H838) NSCLC cells. Cells were treated for 48 hr with sorafenib (1–3 uM), salicylate (1–1.5 mM) or the combination of sorafenib and salicylate with the same concentrations as were used for the individual treatments. Cell lysates were harvested for western blot analysis and probed with the indicated antibodies.

    Int J Cancer 2012 10.1002/ijc.29113.. Sorafenib purchased from Selleck.

    Involvement of EV linc-VLDLR in tumor cell responses to chemotherapy. Cells were incubated with sorafenib, camptothecin, or doxorubicin. EVs were obtained after 24 hours, and qRT-PCR was performed for linc-VLDLR. The bars represent the mean ?SEM of the increase in cell viability from 3 independent studies. *, P < 0.05.

    Mol Cancer Res 2014 12(10), 1377-87. Sorafenib purchased from Selleck.

  • HCC cell-derived exosomes reverse sorafenib-induced apoptosis in hepatoma carcinoma cells in vivo. a Tumors from mice treated with PBS (Control), sorafenib (Sora), sorafenib + LO2-exosomes (Sora + LO2 exo), sorafenib + MHCC-97 L-exosomes (Sora + 97 L exo), and sorafenib + MHCC-97H-exosomes (Sora + 97H exo) were paraffin-embedded and sectioned, followed by staining of apoptotic cell by using TUNEL assays.

    J Exp Clin Cancer Res, 2016, 35(1):159. Sorafenib purchased from Selleck.

    Sorafenib and PX-866 interact to suppress tumor growth in vivo. Mice were PO administered vehicle diluent, sorafenib (25 mg/kg), PX-866 (2 mg/kg), or the drug combination QD for 3 days. Animals were monitored daily and tumor volume determined every fifth day. Tumors from animals were isolated at day 15 and fixed, sectioned (10-um), and stained against proliferation (Ki67 staining), phospho-ERK1/2 and phospho-AKT staining, the levels of tumor cell apoptosis/cleaved caspase 3, as well as with H&E and 4′,6-diamidino-2-phenylindole (DAPI).

    Mol Pharmacol 2013 84(4), 562-71. Sorafenib purchased from Selleck.

  • Effects of sorafenib or sunitinib on LicA-induced cell death, ER stress responses, PLCc1, Ca2+, and ROS in HepG2 cells. HepG2 cells were pretreated with sorafenib or sunitinib for 1 h, then treated with LicA or TG for 1 h (for P-eIF2a and P-PLCc1) or 24 h (for CHOP, ATF6a(p90), and caspase-4). The cell lysates were subjected to Western blot analyses using antibodies against CHOP, ATF6a(p90), caspase-4(C), P-eIF2a, and b-actin.

    Apoptosis 2014 19(4), 682-97. Sorafenib purchased from Selleck.

    PLoS One 2013 8(1), e54595. Sorafenib purchased from Selleck.

  • (C) Western blotting revealed the expression levels of p-AKT, p-ERK1/2 and cleaved PARP in HUH-7 and R-HUH-7 HCC cell lines, these cell lines were treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h. (D) Western blotting revealed the expression levels of p-AKT, p-ERK1/2 and cleaved PARP in SK-HEP-1 and R-SK-HEP-1 HCC cell lines, these cell lines were treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h. (E) HUH-7 hepatoma cells treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h; proportions of apoptotic cells were calculated after cell cytotoxicity assay. (F) SK-HEP-1 hepatoma cells treated with three different concentrations of sorafenib (0, 5, and 10 μM) for 24 h; proportions of apoptotic cells were calculated after cell cytotoxicity assay. Data were expressed as mean ± standard deviation of each experiment in triplicate. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. Sorafenib purchased from Selleck.

Purity & Quality Control

Choose Selective Raf Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.
Targets
Raf-1 [1]
(Cell-free assay)
mVEGFR2(Flk1) [1]
(Cell-free assay)
mVEGFR3 [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
B-Raf (V599E) [1]
(Cell-free assay)
6 nM 15 nM 20 nM 22 nM 38 nM
In vitro

Sorafenib inhibits both wild-type and V599E mutant B-Raf activity with IC50 of 22 nM and 38 nM, respectively. Sorafenib also potently inhibits mVEGFR2 (Flk-1), mVEGFR3, mPDGFRβ, Flt3, and c-Kit with IC50 of 15 nM, 20 nM, 57 nM, 58 nM, and 68 nM, respectively. Sorafenib weakly inhibits FGFR-1 with IC50 of 580 nM. Sorafenib tosylate is not active against ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-Met, PKB, PKA, cdk1/cyclinB, PKCα, PKCγ, and pim-1. Sorafenib markedly inhibits VEGFR2 phosphorylation in NIH 3T3 cells with IC50 of 30 nM, and Flt-3 phosphorylation in HEK-293 cells with IC50 of 20 nM. Sorafenib potently blocks MEK 1/2 and ERK 1/2 phosphorylation in most cell lines but not in A549 or H460 cells, while having no effect on inhibition of the PKB pathway. Sorafenib inhibits the proliferation of HAoSMC and MDA-MB-231 cells with IC50 of 0.28 μM and 2.6 μM, respectively. [1] In addition to inhibition of the RAF/MEK/ERK signaling pathway, Sorafenib significantly inhibits the phosphorylation of eIF4E and down-regulates Mcl-1 levels in hepatocellular carcinoma (HCC) cells in a MEK/ERK-independent manner. Sorafenib inhibits the proliferation of PLC/PRF/5 and HepG2 cells with IC50 of 6.3 μM and 4.5 μM, respectively, and leads to the significant induction of apoptosis. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NVjVW3V1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXaVm1KSzVyPUCuNFAxODB|MEOg{txO MmHqV2FPT0WU
MONO-MAC-6 MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTPTWM2OD1yLkCwOFE5KM7:TR?= NVjqdmJnW0GQR1XS
ALL-PO MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HSTGlEPTB;MD6wN|E5PCEQvF2= NIq1fpBUSU6JRWK=
NKM-1 NU\2R453T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7wTWM2OD1yLkC3OFE3KM7:TR?= NHTZPI1USU6JRWK=
CGTH-W-1 M{D3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwMkWwNlIh|ryP M4nFR3NCVkeHUh?=
BB65-RCC MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTBwNEewO|Mh|ryP MlraV2FPT0WU
NOS-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrLTWM2OD1yLkW2N|Yh|ryP M{LIVnNCVkeHUh?=
SH-4 MoLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3QZYFwUUN3ME2wMlY2PjF|IN88US=> NHPVNJVUSU6JRWK=
HOP-62 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTBwOEWwPFgh|ryP MYLTRW5ITVJ?
HCC2998 M4fMbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4C4dGlEPTB;MD64PFgyQCEQvF2= MkjMV2FPT0WU
GDM-1 NYHqdYFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTBwOUC2PVgh|ryP MXfTRW5ITVJ?
KM12 Mkm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTFwMEKwPVgh|ryP MlPkV2FPT0WU
LB2518-MEL NEC1[29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTFwMkC4NFkh|ryP NUPHNJlUW0GQR1XS
NCI-H1436 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fPZmlEPTB;MT6yNVY4QCEQvF2= MoP6V2FPT0WU
EM-2 MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDEXotGUUN3ME2xMlM2PTd6IN88US=> M1zqN3NCVkeHUh?=
LAMA-84 M2Xye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLhTWM2OD1zLkO3OlQ5KM7:TR?= MVjTRW5ITVJ?
KG-1 Mm[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHy2UIxKSzVyPUGuOFc6OzVizszN MVzTRW5ITVJ?
A388 NH\TXVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTFwNUmxOlUh|ryP NVjpXZdWW0GQR1XS
no-10 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjrW2VKSzVyPUGuOlE4OjZizszN MU\TRW5ITVJ?
SF126 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLzTWM2OD1zLk[zPFEzKM7:TR?= MnrBV2FPT0WU
MEG-01 NEXre2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\xTWM2OD1zLkiwPVgh|ryP NGPKW4FUSU6JRWK=
A3-KAW M4TUdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTFwOEi0NkDPxE1? MUXTRW5ITVJ?
D-247MG M1n5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYf3OIdSUUN3ME2yMlE1PDhizszN M3;QVnNCVkeHUh?=
OVCAR-4 MlrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHkTmtKSzVyPUKuNlE{QTNizszN NHmw[lRUSU6JRWK=
NCI-SNU-1 NF;0VWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrLOpJKSzVyPUKuN|E3OiEQvF2= MXHTRW5ITVJ?
NCI-H2171 NH;YUFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PYemlEPTB;Mj6zPVc3PCEQvF2= M2LkOnNCVkeHUh?=
SIG-M5 NHTrRYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPzWYFKSzVyPUKuOFIzPDJizszN M3WwenNCVkeHUh?=
BE-13 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYr3elJkUUN3ME2yMlY6PjB7IN88US=> Ml7yV2FPT0WU
K052 Mof1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDBWJNKSzVyPUKuO|Q3OTZizszN NIr3eWhUSU6JRWK=
L-540 M1TVbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XTeWlEPTB;Mj63OVc5QSEQvF2= NELhXnhUSU6JRWK=
KMOE-2 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrHW4pKSzVyPUKuPFE{PSEQvF2= NGOze3BUSU6JRWK=
MFH-ino NGXjbJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PyR2lEPTB;Mj65NlE5PSEQvF2= MmLlV2FPT0WU
HL-60 Ml7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4S2NmlEPTB;Mz6wOlI6QSEQvF2= MYPTRW5ITVJ?
HCC2218 M1y0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETDeopKSzVyPUOuNVIxODNizszN NEPVTVZUSU6JRWK=
TE-5 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrPWG01UUN3ME2zMlE{OTZ{IN88US=> MVnTRW5ITVJ?
MZ1-PC NIK1T3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TPdWlEPTB;Mz60O|UxQSEQvF2= M3TJ[XNCVkeHUh?=
MRK-nu-1 M2X1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInaUphKSzVyPUOuOlE1PjhizszN M1G5THNCVkeHUh?=
MZ7-mel MnfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTNwNk[wPVkh|ryP MlX6V2FPT0WU
BC-1 Mnz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXHV3EzUUN3ME2zMlc1ODJizszN NES3UoNUSU6JRWK=
ST486 NXjXdGpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XZ[mlEPTB;Mz64N|Y4OyEQvF2= M3LZdHNCVkeHUh?=
KS-1 NEflb21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjEWGh5UUN3ME2zMlg5OTl6IN88US=> M1fnUnNCVkeHUh?=
SK-NEP-1 NH;udI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDad|hKSzVyPUSuNVY5OTVizszN NYHpd3BkW0GQR1XS
BC-3 M4PQbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7nOYp[UUN3ME20MlI{OzlzIN88US=> Ml7LV2FPT0WU
NCI-H1581 MoHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXQUGJKSzVyPUSuNlg4QThizszN M17NbXNCVkeHUh?=
MHH-PREB-1 Ml\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjOdpZGUUN3ME20MlQxPDh2IN88US=> MWPTRW5ITVJ?
NOMO-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfkPZhPUUN3ME20MlQ5QTB3IN88US=> MYTTRW5ITVJ?
QIMR-WIL NWi3SoJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M32wXmlEPTB;NT6wO|I6PCEQvF2= MoX5V2FPT0WU
SF539 M4jBcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvFTWM2OD13LkGzNlI4KM7:TR?= NEjGSm5USU6JRWK=
TE-12 M2P3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHOTWM2OD13LkK0PVI6KM7:TR?= MUfTRW5ITVJ?
NCI-H510A NVLFUlc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTVwNEG2PFUh|ryP M2LVc3NCVkeHUh?=
JAR MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmO3TWM2OD13LkWwPFI1KM7:TR?= MXjTRW5ITVJ?
no-11 M1PtVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXLUVEyUUN3ME21Mlc{PTZ6IN88US=> NX7wPJU4W0GQR1XS
BV-173 NFnYR2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTVwOUW2PFIh|ryP Mn;tV2FPT0WU
SR NFPm[GRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnNcnQ{UUN3ME22MlAxPjd6IN88US=> NIPPUY9USU6JRWK=
MOLT-16 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLYeGNiUUN3ME22MlI2OjZ4IN88US=> MnT2V2FPT0WU
MZ2-MEL NVrQOJI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzBWopkUUN3ME22MlMyQDN7IN88US=> M1zpV3NCVkeHUh?=
SW954 MoryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPXTWM2OD14LkS1PFY3KM7:TR?= MVnTRW5ITVJ?
ML-2 NWqwNZdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHUeGJKSzVyPU[uOVI5PDlizszN MXPTRW5ITVJ?
OCI-AML2 M4L0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fjS2lEPTB;Nj62NVA3OiEQvF2= NGPiT21USU6JRWK=
SIMA MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2n1PGlEPTB;Nz6wNFExOSEQvF2= MoGzV2FPT0WU
DOHH-2 NYPkZ|FsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1i0TmlEPTB;Nz6wOVY4PiEQvF2= MYrTRW5ITVJ?
697 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XO[GlEPTB;Nz6wOVk5QSEQvF2= NVPUUll6W0GQR1XS
NB1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjGS5pKSzVyPUeuOFA1ODdizszN NFzBOVFUSU6JRWK=
D-392MG NXTwcXJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;tSFMxUUN3ME23MlYzPjZ|IN88US=> M3fJbHNCVkeHUh?=
ES8 Mn;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7XTWM2OD15Lke2OVA{KM7:TR?= Mn\kV2FPT0WU
RPMI-8226 M3j0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XVSmlEPTB;Nz64OFUyOSEQvF2= MV;TRW5ITVJ?
IST-MEL1 M3fvSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYP1VmVUUUN3ME24MlQxODB{IN88US=> NInZ[4NUSU6JRWK=
NB14 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfuTWM2OD16Lk[zNVM{KM7:TR?= Mn\oV2FPT0WU
HD-MY-Z Ml34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnBdWEyUUN3ME24MlY{PzR4IN88US=> NInLS|VUSU6JRWK=
TE-10 M2CyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRThwN{[zOVMh|ryP MYDTRW5ITVJ?
LC-1F MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTlwMUC4N|Qh|ryP M4PtV3NCVkeHUh?=
OS-RC-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;zXWlEPTB;OT6xNVI1OyEQvF2= MXPTRW5ITVJ?
NCI-SNU-16 NH3zV29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWK2XHlbUUN3ME25MlIyODJ4IN88US=> NIX5RW9USU6JRWK=
SHP-77 NUXUfYg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NESzU3VKSzVyPUmuO|E3PjJizszN NUTXeYQ{W0GQR1XS
A4-Fuk Mn\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLjTWM2OD17Lke1OlEh|ryP NVj1fHRqW0GQR1XS
NB6 NHHtZlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LVTWlEPTB;OT63OlAzQSEQvF2= M3TROXNCVkeHUh?=
JiyoyeP-2003 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDSTWM2OD1zMD60O|Q2KM7:TR?= MXrTRW5ITVJ?
DMS-114 NU\lN2xiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrWcVRKSzVyPUGwMlU1PDFizszN NF7uTYhUSU6JRWK=
NB7 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7sV5dDUUN3ME2xNE44PTJ4IN88US=> Mn3GV2FPT0WU
NCI-H747 NVXtV3lVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LXUmlEPTB;MUGuNVIyPiEQvF2= NWjyXZhUW0GQR1XS
HH M3q5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXOTWM2OD1zMT6zPFc3KM7:TR?= MmPCV2FPT0WU
EW-18 NVjtOmtUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfpZ5ZvUUN3ME2xNU46ODR2IN88US=> MmnQV2FPT0WU
CHP-126 NH;0VWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;CfZFJUUN3ME2xNU46PzN6IN88US=> M4nGeXNCVkeHUh?=
NTERA-S-cl-D1 NVTZPHdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;TRmlEPTB;MUKuNFI4QCEQvF2= NEe3PWVUSU6JRWK=
DEL MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHP6N5RKSzVyPUGyMlA6QDVizszN NXrqZphTW0GQR1XS
LU-139 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTF{LkW0NVMh|ryP NI\BSpdUSU6JRWK=
P30-OHK NVLZeGE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTF{LkW0O|kh|ryP M1TxT3NCVkeHUh?=
NCI-H1522 NYDCU3hRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[yTWM2OD1zMj63OFYh|ryP NXmwfmVOW0GQR1XS
NCI-H1299 MnHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3v3XmlEPTB;MUOuNlkyOSEQvF2= NWfqTYdxW0GQR1XS
UACC-257 NUe4T|A6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTF|LkWxNlYh|ryP M4nSS3NCVkeHUh?=
Calu-6 M2nlN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7OR2Q6UUN3ME2xN{43ODR4IN88US=> MnzIV2FPT0WU
NCI-H1882 NGTQfGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTF|Lki1OVUh|ryP M{G1cXNCVkeHUh?=
BB30-HNC MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTF2LkC2NFkh|ryP M1jsOXNCVkeHUh?=
ES1 NVL5ZXRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHWPZZKSzVyPUG0MlE2PTFizszN M3T5SHNCVkeHUh?=
NCI-H1694 MmG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHoTWM2OD1zND60PFEyKM7:TR?= M4TndnNCVkeHUh?=
IST-SL1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnYTWM2OD1zND65OlE3KM7:TR?= NIi0cmtUSU6JRWK=
ECC4 NILEUHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXBVI9vUUN3ME2xOU4xPTV6IN88US=> M37MNHNCVkeHUh?=
MDA-MB-134-VI NH3uSYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELRWYFKSzVyPUG1MlQyOzFizszN MUXTRW5ITVJ?
SCH NV;LZZdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkL3TWM2OD1zNT60O|I5KM7:TR?= MX3TRW5ITVJ?
SK-N-FI NInsWmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nBXWlEPTB;MUWuOlU{PCEQvF2= MV7TRW5ITVJ?
HDLM-2 NGXhXWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfRS29LUUN3ME2xOk4xPzF2IN88US=> NVW0SoVSW0GQR1XS
Ramos-2G6-4C10 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fHO2lEPTB;MU[uNVI6PyEQvF2= NWiySWtnW0GQR1XS
EW-24 NUPybmtnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofXTWM2OD1zNj6xOlYyKM7:TR?= MWPTRW5ITVJ?
NCI-H2141 NIHkN|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vrbmlEPTB;MU[uNVg6KM7:TR?= NVvVVW1QW0GQR1XS
LC4-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWL6UGpXUUN3ME2xOk43OTF7IN88US=> MVLTRW5ITVJ?
HT-144 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzodVRPUUN3ME2xO{4xODZizszN MV\TRW5ITVJ?
SK-MEL-1 NFq0XopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkf2TWM2OD1zNz6wNFczKM7:TR?= M1nnWnNCVkeHUh?=
SCC-15 NXnHeGVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfX[phnUUN3ME2xO{4yPjN6IN88US=> NHfydZFUSU6JRWK=
C8166 NHrlSVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DI[2lEPTB;MUeuOlg{OyEQvF2= NV3WZ5JWW0GQR1XS
GOTO MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\hNGlEPTB;MUeuPFM1PCEQvF2= NWm1UJI1W0GQR1XS
COR-L279 MlvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DBWmlEPTB;MUiuNVM3OiEQvF2= M1XDPHNCVkeHUh?=
K-562 NGrE[3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTjd3RKSzVyPUG4MlcyPDNizszN M2nhN3NCVkeHUh?=
ES3 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEG1WVJKSzVyPUG4MlgxPDFizszN Mmi0V2FPT0WU
LU-165 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnntTWM2OD1zOT63NFA5KM7:TR?= M13HTHNCVkeHUh?=
KM-H2 NInkdmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDUcVFZUUN3ME2yNE4{OTh2IN88US=> MnfDV2FPT0WU
RL Mof1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzFPFJKSzVyPUKwMlk3QTJizszN NIflNZFUSU6JRWK=
EW-3 NY\CTFN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTJzLkG4PFkh|ryP MljlV2FPT0WU
A101D MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXBT|ZSUUN3ME2yNU4{PzV{IN88US=> NGK5SXVUSU6JRWK=
HUTU-80 M1LDNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTJzLkO5OFYh|ryP MYfTRW5ITVJ?
NCI-H23 NG\qdJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLocFBKSzVyPUKxMlM6QTJizszN MlPpV2FPT0WU
PF-382 NUThUI5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPoZ2ZKSzVyPUKxMlQ1ODNizszN MYTTRW5ITVJ?
LB373-MEL-D MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVv2PJp4UUN3ME2yNU42PjF3IN88US=> M{LPWXNCVkeHUh?=
TE-8 Mn\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLpTWM2OD1{MT62N|k1KM7:TR?= M32wWnNCVkeHUh?=
TE-9 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\yUXlKSzVyPUKxMlg2OTNizszN NITaSJpUSU6JRWK=
Daudi NWfiZ5o2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7mUIk5UUN3ME2yNU46OzB2IN88US=> MnvkV2FPT0WU
D-542MG NHfhdJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTJ{LkCyOVYh|ryP M3jiXnNCVkeHUh?=
U-698-M M4HoZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfkTppwUUN3ME2yNk41PjB|IN88US=> M2nXfnNCVkeHUh?=
ES6 NUj0RVFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLu[|dwUUN3ME2yNk44OzZ4IN88US=> NFrXSpRUSU6JRWK=
DU-4475 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTJ|Lki4PVch|ryP M1jTUHNCVkeHUh?=
ECC12 M2jDUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfmUWFKSzVyPUK0MlI5ODNizszN M3HxfnNCVkeHUh?=
C2BBe1 NG\icmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfFTnU6UUN3ME2yOE4{OjN7IN88US=> M1PmdHNCVkeHUh?=
IST-SL2 NVfmfXRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1:yVGlEPTB;MkSuOFM3OiEQvF2= M{TYVHNCVkeHUh?=
DJM-1 NVfR[ldDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLVNJFKSzVyPUK0MlUzOjFizszN MljoV2FPT0WU
DMS-153 M2fPW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHf1V|hKSzVyPUK0Mlg3OTRizszN M12yRnNCVkeHUh?=
NB13 NXPXXlRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHKxWpVKSzVyPUK1MlAzPjVizszN MX3TRW5ITVJ?
SK-N-DZ M3H2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LYWmlEPTB;Mk[uN|QyPCEQvF2= MkHBV2FPT0WU
COR-L88 MoftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHDTWM2OD1{Nj61O|k3KM7:TR?= M3u4XHNCVkeHUh?=
LU-65 NXvFZ3pJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTJ4Lki1N|Uh|ryP NGD5TVNUSU6JRWK=
TGBC1TKB MkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfYTWM2OD1{Nj65PFI5KM7:TR?= MYfTRW5ITVJ?
THP-1 NWrrRpVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrQV3JKSzVyPUK3MlIyPDFizszN NIPJbmdUSU6JRWK=
ONS-76 M2XmXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrkTFRyUUN3ME2yO{4{OzJizszN MnftV2FPT0WU
LC-2-ad M2TSfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LkU2lEPTB;MkeuOlI{OSEQvF2= M3Ps[HNCVkeHUh?=
EW-13 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TGNmlEPTB;MkmuNVc1PiEQvF2= MXnTRW5ITVJ?
MS-1 NY\GTIdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITyPIlKSzVyPUOwMlczPzhizszN MoTNV2FPT0WU
NCI-H2227 NVviWnBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTNyLkm4NFYh|ryP NHXh[4FUSU6JRWK=
LXF-289 NXq0dXZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDkUY5nUUN3ME2zNU41PDl{IN88US=> MnvVV2FPT0WU
MC116 MlHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoftTWM2OD1|Mj6wPFI3KM7:TR?= MojMV2FPT0WU
EVSA-T NXvB[2xnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVizUohDUUN3ME2zNk4zPTh3IN88US=> MYfTRW5ITVJ?
CTB-1 NYn5SIlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{KzemlEPTB;M{OuNVExOSEQvF2= NY\S[nNnW0GQR1XS
COLO-320-HSR M1zDeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXtTWM2OD1|Mz6xOlA{KM7:TR?= NYLrXVNJW0GQR1XS
NCI-H2196 NX;ROIFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfQbG5KSzVyPUOzMlI2PTdizszN MYfTRW5ITVJ?
LB2241-RCC MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTN|LkOxN|Uh|ryP MmDjV2FPT0WU
LS-513 NEnyU2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIThZVJKSzVyPUOzMlg3OzhizszN NWXheYVFW0GQR1XS
LP-1 NWXwPZpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGr2O2VKSzVyPUOzMlk6PTZizszN NYTvOGJoW0GQR1XS
A253 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DDN2lEPTB;M{SuNlI6PiEQvF2= M3vsfHNCVkeHUh?=
SK-MM-2 NHLSW4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;lZYNKSzVyPUO0Mlk1PTFizszN NIrZNWxUSU6JRWK=
NCI-H1963 Mlq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTN3LkOwO|Ih|ryP Ml\rV2FPT0WU
MMAC-SF MoC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfhcZBnUUN3ME2zOU45Pzh3IN88US=> NH6zZ5ZUSU6JRWK=
LB831-BLC NX\DNXBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTN4LkC2OVQh|ryP NX\DdHdiW0GQR1XS
WSU-NHL MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfxTXFKSzVyPUO2MlE3PCEQvF2= MUXTRW5ITVJ?
CESS M2PuTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTN4LkK4OFgh|ryP NHzS[pRUSU6JRWK=
NEC8 NVqzOppNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnm0TWM2OD1|Nj61PFM2KM7:TR?= MnfIV2FPT0WU
KNS-42 NE\Dc2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2[x[GlEPTB;M{euNVI{PyEQvF2= NFjkVHZUSU6JRWK=
MHH-CALL-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDvTWM2OD1|Nz6xPFIyKM7:TR?= M2H3c3NCVkeHUh?=
K5 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;MTWM2OD1|OD60N{DPxE1? NV;vUHVoW0GQR1XS
CP66-MEL Mli0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPBfXZKSzVyPUO5MlA4OzNizszN MorBV2FPT0WU
OPM-2 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTN7Lki0N|Ih|ryP M{W2dnNCVkeHUh?=
IST-MES1 NEPFOpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWn4OI8xUUN3ME20NE4{ODl4IN88US=> MVjTRW5ITVJ?
EC-GI-10 M4i1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3qzOmlEPTB;NEGuOVgxPSEQvF2= MVjTRW5ITVJ?
CTV-1 NILF[JRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvmWINsUUN3ME20Nk45PDB4IN88US=> M3fSTHNCVkeHUh?=
DG-75 NES3PYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLLTWM2OD12Mz63OVk2KM7:TR?= MYXTRW5ITVJ?
KNS-81-FD NX2wTJFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXsR4QzUUN3ME20OU41ODV6IN88US=> M4LReHNCVkeHUh?=
NCI-H82 NXLmdFJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4H1W2lEPTB;NEWuOVc2QCEQvF2= NW\WcJd6W0GQR1XS
RPMI-8866 M3\oc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7QTWM2OD12Nj6xPFc{KM7:TR?= MUDTRW5ITVJ?
ACN NVHFUot7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7wTWM2OD12Nj60N|Qh|ryP NIrKXWFUSU6JRWK=
NCI-H1395 NGD5RXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLh[G1IUUN3ME20Ok41PzV4IN88US=> NUPJV5ZpW0GQR1XS
NCI-H209 MnLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvncW5KSzVyPUS3MlE1ODVizszN M{CwdHNCVkeHUh?=
TGW MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofSTWM2OD12OT6wO|kyKM7:TR?= MWfTRW5ITVJ?
NCI-H748 NWnJPFhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXM[nU3UUN3ME20PU41PzV|IN88US=> NHLYS2FUSU6JRWK=
EKVX NWXxelF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TVWmlEPTB;NEmuOlYzQCEQvF2= M3;1SXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Oral administration of Sorafenib (~60 mg/kg) demonstrates broad spectrum, dose-dependent anti-tumor activity against a variety of human tumor xenograft models including MDA-MB-231, Colo-205, HT-29, DLD-1, NCI-H460, and A549, with no evidence of toxicity. In association with the anti-tumor efficacy, Sorafenib treatment potently inhibits MEK 1/2 phosphorylation and pERK 1/2 levels in HT-29 and MDA-MB-231 xenografts but not in Colo-205 xenografts, and significantly suppresses tumor microvessel area (MVA) and microvessel density (MVD) in MDA MB-231, HT-29 and Colo-205 tumor xenografts. [1] Sorafenib treatment produces dose-dependent growth inhibition of PLC/PRF/5 tumor xenografts in SCID mice with TGIs of 49% and 78% at 10 mg/kg and 30 mg/kg, respectively, consistent with the inhibition of ERK and eIF4E phosphorylation, reduction of the microvessel area, and induction of tumor cell apoptosis. [2] Sorafenib sensitizes bax-/- cells to TRAIL in a dose-dependent manner, through a mechanism involving down-regulating NF-κB mediated Mcl-1 and cIAP2 expression. Combining Sorafenib (30-60 mg/kg) with TRAIL (5 mg/kg) show dramatic efficacy in TRAIL-resistant HCT116 bax-/- and HT29 tumor xenografts. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Biochemical assays:

Recombinant baculoviruses expressing Raf-1 (residues 305–648) and B-Raf (residues 409–765) are purified as fusion proteins. Full-length human MEK-1 is generated by PCR and purified as a fusion protein from Escherichia coli lysates. Sorafenib tosylate is added to a mixture of Raf-1 (80 ng), or B-Raf (80 ng) with MEK-1 (1 μg) in assay buffer [20 mM Tris (pH 8.2), 100 mM NaCl, 5 mM MgCl2, and 0.15% β-mercaptoethanol] at a final concentration of 1% DMSO. The Raf kinase assay (final volume of 50 μL) is initiated by adding 25 μL of 10 μM γ[33P]ATP (400 Ci/mol) and incubated at 32 °C for 25 minutes. Phosphorylated MEK-1 is harvested by filtration onto a phosphocellulose mat, and 1% phosphoric acid is used to wash away unbound radioactivity. After drying by microwave heating, a β-plate counter is used to quantify filter-bound radioactivity. Human VEGFR2 (KDR) kinase domain is expressed and purified from Sf9 lysates. Time-resolved fluorescence energy transfer assays for VEGFR2 are performed in 96-well opaque plates in the time-resolved fluorescence energy transfer format. Final reaction conditions are as follows: 1 to 10 μM ATP, 25 nM poly GT-biotin, 2 nM Europium-labeled phospho (p)-Tyr antibody (PY20), 10 nM APC, 1 to 7 nM cytoplasmic kinase domain in final concentrations of 1% DMSO, 50 mM HEPES (pH 7.5), 10 mM MgCl2, 0.1 mM EDTA, 0.015% Brij-35, 0.1 mg/mL BSA, and 0.1% β-mercaptoethanol. Reaction volumes are 100 μL and are initiated by addition of enzyme. Plates are read at both 615 and 665 nM on a Perkin-Elmer VictorV Multilabel counter at ~1.5 to 2.0 hours after reaction initiation. Signal is calculated as a ratio: (665 nm/615 nM) × 10,000 for each well. For IC50 generation, Sorafenib tosylate is added before the enzyme initiation. A 50-fold stock plate is made with Sorafenib tosylate serially diluted 1:3 in a 50% DMSO/50% distilled water solution. Final Sorafenib tosylate concentrations range from 10 μM to 4.56 nM in 1% DMSO.
Cell Research:

[1]

+ Expand
  • Cell lines: MDA-MB-231, and HAoSMC
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to increasing concentrations of Sorafenib tosylate for 72 hours. Cell number is quantitated using the Cell TiterGlo ATP Luminescent assay kit. This assay measures the number of viable cells per well by measurement of luminescent signal based on amount of cellular ATP.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Female NCr-nu/nu mice implanted s.c. with MDA-MB-231, Colo-205, HT-29, H460, or A549 cells
  • Formulation: Dissolved in Cremophor EL/ethanol (50:50) as 4-fold (4 × stock solution, and diluted to 1 × with water
  • Dosages: ~60 mg/kg
  • Administration: Orally once daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 63 mg/mL warmed (135.53 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 5% DMSO+45% PEG 400+ddH2O 3mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 464.82
Formula

C21H16ClF3N4O3

CAS No. 284461-73-0
Storage powder
in solvent
Synonyms BAY 43-9006

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00727233 Completed Neurofibromatosis Type I|Plexiform Neurofibroma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 8, 2008 Phase 1
NCT02989870 Not yet recruiting HepatoCellular Carcinoma|Unresectable HepatoCellular Carcinoma|Liver Cancer H. Lee Moffitt Cancer Center and Research Institute|National Comprehensive Cancer Network April 30, 2017 Phase 1
NCT01445080 Completed Leukemia|With AML and FLT3-ITD Mutations National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 23, 2006 Phase 1
NCT01434602 Recruiting Brain Tumor|Glioblastoma|Anaplastic Glioma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 21, 2015 Phase 1|Phase 2
NCT02988440 Not yet recruiting Hepatocellular Carcinoma Novartis Pharmaceuticals|Novartis May 2017 Phase 1
NCT03037437 Not yet recruiting Hepatocellular Cancer The University of Texas Health Science Center at San Antonio January 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Raf Signaling Pathway Map

Related Raf Products

Tags: buy Sorafenib | Sorafenib supplier | purchase Sorafenib | Sorafenib cost | Sorafenib manufacturer | order Sorafenib | Sorafenib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID